Subscribe to our Newsletters !!
There is one fact about life on Earth we cannot es
In this application note, we demonstrate how the C
The Nobel Prize in Physiology or Medicine awarded
In today’s rapidly evolving bioprocessing landsc
Alembic Pharmaceutica
Tofu has been a favorite food for vegetarians and
Dear Readers, Welcome to the latest issue of Mi
Siberia’s Vector virology institute on September 8 finished early-stage human trials, called Phase II, of a second possible Russian vaccine against COVID-19, the state consumer safety watchdog was cited by the Interfax news agency as saying.
Russia registered its first vaccine candidate, developed by Moscow’s Gamaleya Institute, in August after finishing early-stage human trials.
“Today… the last group of 20 volunteers was released from hospital,” watchdog Rospotrebnadzor said in a statement.
“All 100 volunteers were vaccinated with two doses and have completed a 23-day monitoring period in hospital. The volunteers are feeling great.”
